OpenAI

At FieldAI, we bring together top-tier talent from NASA JPL, DeepMind, Tesla, and NVIDIA to build the future of embodied AI. Our team thrives on tackling the toughest challenges in unstructured environments, where we've developed first-of-its-kind AI and robot autonomy solutions that can navigate caves without satellite information or prior maps. We're a collaborative group of engineers, researchers, and field deployment experts who believe in shipping real-world robotic AI across the globe. Our culture emphasizes deep technical excellence combined with practical field application - we don't just write code, we deploy it to the most demanding industrial and defense environments. We're driven by a shared mission to enable unprecedented productivity, safety, and efficiency by bringing autonomy to challenging real-world conditions. Our physics-first approach means we value robustness and resilience in everything we build. Having grown from approximately 30 people at the end of 2024 to 130 team members in 2025, we maintain a collaborative environment where individual contributions have real impact. Whether developing Field Foundation Models or scaling our technology for government and defense applications through Field AI Federal, our team members tackle complex problems with creativity and determination.

In 1999, two science-based companies with shared visions came together to form AstraZeneca: Sweden's Astra AB and the UK's Zeneca Group PLC. This strategic merger combined decades of pharmaceutical expertise, creating a global powerhouse uniquely positioned to push the boundaries of scientific discovery. What began as a union of strengths has evolved into a relentless pursuit of breakthrough therapies, with the company investing billions annually in research and development to transform patient outcomes across oncology, biopharmaceuticals, respiratory, and rare diseases. Today, AstraZeneca stands at the forefront of precision medicine and next-generation therapeutics, harnessing the power of data science, AI, and innovative technologies like cell therapies. With 197 projects in the pipeline and 16 blockbuster medicines, the company operates from six strategic R&D centres spanning Cambridge, Gothenburg, Gaithersburg, Boston, Shanghai, and Beijing. Their bold aspiration to deliver 20 new medicines by 2030 reflects an unwavering commitment to following the science and putting patients first - values that have driven every decision since that pivotal merger more than two decades ago.

At SOSi, we believe that solving the world's toughest challenges requires a culture of innovation and resilience. Our people-first approach drives everything we do - from delivering mission-critical solutions in aerospace and defense to supporting our nation's allies worldwide. We empower our employees to break through barriers and develop bold solutions that make a real impact, operating with the agility of a founder-owned company while delivering the depth and breadth of a large enterprise. Our team thrives in an environment where ownership and collaboration intersect. Whether working on zero-trust architectures, intelligence operations, or logistics in contested environments, SOSi team members are encouraged to act fast and think boldly. We're built to prevail through technical excellence and unwavering commitment to our mission, fostering a workplace where diverse perspectives fuel innovation and where every team member has the opportunity to shape the future of defense and government services.

At Agenus, we're driven by a singular, unwavering mission: to end the suffering of cancer patients. For over 30 years, our team of scientists, researchers, and professionals has been united by this purpose, working collaboratively across the US and Europe to discover, develop, and manufacture breakthrough immuno-oncology therapies. Our research and innovation engine has built a comprehensive pipeline of novel immunotherapies that empower the body to recognize and eliminate disease. We believe that the key to transforming cancer treatment lies in harnessing the full power of the immune system - activating it to do what it was meant to do. Our culture is defined by scientific excellence, relentless innovation, and an unwavering focus on patients. We thrive on tackling the toughest challenges in oncology, particularly in areas where current therapies fall short - cold tumors and late-stage cancers that have resisted traditional treatments. The people who thrive here are those who share our passion for making a meaningful difference, who embrace collaboration across disciplines, and who are motivated by the potential to deliver curative therapies to patients who need them most. Every day, we're pushing the boundaries of what's possible in immunotherapy, united by our vision of a future where more patients live longer, fuller lives.

At Novonesis, we believe that solutions rooted in biology are the key to tackling the biggest challenges our world faces. Our team of more than 10,000 colleagues across 30+ industries works together to transform how the world produces, consumes, and lives. We operate with a culture of collaboration and innovation, drawing on over a century of combined expertise from our heritage companies. Our people thrive in an environment where sustainability is not just a goal but a fundamental part of how we work - where every contribution helps build healthier lives and a healthier planet. We are inherently sustainable because we draw from nature, and we embrace the diverse perspectives that drive our innovation forward. Our inclusive culture fosters belonging and respect, ensuring that everyone can bring their authentic selves to work while making meaningful impact. Whether developing enzymes, functional proteins, or microorganisms, we operate with the conviction that biology holds the answers to humanity's most pressing challenges. We empower our teams with real ownership and cross-functional collaboration, optimizing for impact rather than hierarchy.

ARX Robotics builds Europe's leading autonomous mobile robotics and a comprehensive digitalization platform for modernizing legacy fleets. The company develops deployment-ready systems and software that strengthen Europe's technological resilience across every mission, securing European sovereignty and protecting freedom and democracy through advanced defense technology. ARX specializes in dual-use autonomous unmanned ground systems and sensors for the European defense sector, assisting NATO armies and civilian first responders in tackling their most challenging problems. The company's product portfolio includes Gereon RCS, Mithra OS for fleet modernization, and Hector - a scalable land capability platform. With headquarters in Munich and offices in Berlin, London, and Kyiv, ARX Robotics drives innovation through swift development, quick decision-making, and efficient execution.